Lunai Bioworks Inc. (NASDAQ:LNAI) Sees Significant Decrease in Short Interest

Lunai Bioworks Inc. (NASDAQ:LNAI) was the recipient of a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 150,195 shares, a decline of 47.7% from the June 15th total of 287,256 shares. Based on an average daily trading volume, of 4,793,299 shares, the short-interest ratio is currently 0.0 days. Approximately 3.3% of the company’s shares are sold short.

Analysts Set New Price Targets

LNAI has been the subject of a number of analyst reports. Wall Street Zen upgraded Lunai Bioworks to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Lunai Bioworks

A hedge fund recently bought a new position in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Lunai Bioworks Price Performance

NASDAQ LNAI traded down $0.06 during mid-day trading on Friday, reaching $2.82. 15,821 shares of the stock were exchanged, compared to its average volume of 1,633,758. Lunai Bioworks has a one year low of $1.21 and a one year high of $28.00. The stock has a 50 day simple moving average of $2.83 and a 200-day simple moving average of $3.91. The stock has a market cap of $12.77 million, a P/E ratio of -7.05 and a beta of 0.37.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The business had revenue of $0.02 million for the quarter.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.